Takara Bio, Inc. engages in development and marketing of genetic engineering technologies. The company is headquartered in Kusatsu-Shi, Shiga-Ken and currently employs 1,779 full-time employees. The company went IPO on 2004-12-07. The firm operates in three business segments. Bioindustry Support segment provides reagents for research (genetic engineering reagents, cell engineering reagents, protein engineering reagents), scientific instruments, contract services and license fees for gene related patents to research institutes, such as universities and companies where biotechnology research and development are conducted. Gene Medicine segment provides gene therapy-related development and sale licensing fees and trial products as an application field of genetic engineering technology and cell engineering technology which is core technology cultivated in development of research reagents. Medical Food and Biotechnology segment provides health food and health food research and development services, license fees for health food related patents, as well as license fees for mushrooms.
Follow-Up Questions
Takara Bio Inc의 CEO는 누구입니까?
Mr. Koichi Nakao은 2007부터 회사에 합류한 Takara Bio Inc의 President입니다.
TKBIF 주식의 가격 성능은 어떻습니까?
TKBIF의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
Takara Bio Inc의 주요 사업 주제나 업종은 무엇입니까?
Takara Bio Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Takara Bio Inc의 시가총액은 얼마입니까?
Takara Bio Inc의 현재 시가총액은 $NaN입니다
Takara Bio Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 5명의 분석가가 Takara Bio Inc에 대한 분석 평가를 실시했으며, 이는 1명의 강력한 매수, 3명의 매수, 4명의 보유, 0명의 매도, 그리고 1명의 강력한 매도를 포함합니다